Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

Circulation. 2017 Sep 19;136(12):1167-1169. doi: 10.1161/CIRCULATIONAHA.117.029529.

Authors

Kristina Striepe¹, Agnes Jumar¹, Christian Ott¹, Marina V Karg¹, Markus P Schneider¹, Dennis Kannenkeril¹, Roland E Schmieder²

Affiliations

¹ From Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany.
² From Department of Nephrology and Hypertension, University Hospital Erlangen, Bavaria, Germany. roland.schmieder@uk-erlangen.de roland.schmieder@fau.de.

PMID: 28923906
DOI: 10.1161/CIRCULATIONAHA.117.029529

No abstract available

Keywords: SGLT-2 inhibitor; central systolic pressure; empagliflozin; pulse wave analysis; type 2 diabetes mellitus.

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Adolescent
Adult
Aged
Benzhydryl Compounds / administration & dosage*
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / drug therapy*
Cardiovascular Diseases / physiopathology
Cross-Over Studies
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / physiopathology
Double-Blind Method
Drug Administration Schedule
Female
Germany
Glucosides / administration & dosage*
Hemodynamics / drug effects*
Humans
Male
Middle Aged
Prospective Studies
Recovery of Function
Sodium-Glucose Transporter 2 Inhibitors / administration & dosage*
Time Factors
Treatment Outcome
Vascular Stiffness / drug effects*
Young Adult

Substances

Benzhydryl Compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
empagliflozin

Associated data

ClinicalTrials.gov/NCT02471963